| |
| |
 |
|
|
| |
|
|
| |
 |
| Cheng
Shujun is currently as a professor of Cancer
Institute (Hospital), Chinese Academy of Medical Sciences
& Peking Union Medical College, Beijing, China,
and Chief Scientist of both China State Key Basic
Research Project “Fundamental investigation of human
carcinogenesis and cancer therapy and prevention”
and Beijing key Cancer Research Project “Tumor biomarker
profiling and human cancer diagnosis and therapy”.
He worked as a visiting scientist in Laboratoire de
Medicine Experimental, Institute de la Recherches
Scientifiques sur le Cancer, France (1978-1981), and
in Department of Pathology, Medical College of Ohio,
USA (1986-1987). He has established a series of short-term
tests for the detection of environmental carcinogens
and anti-carcinogens in China. He was elected as a
Member, Chinese Academy of Engineering in 1999. Dr.
Cheng is the President of Chinese Environmental Mutagen
Society, and Vice President of China Anticancer Association.
He found that the tea catechins showed a significant
inhibitory effect against human genital condylomas
and inflammatory hyperplasia. Based on the invention,
he and his collaborators had received international
patents “Composition for treating condyloma acuminate”
in 1998. This invention had been approved to go for
clinical phase III trial by US FDA. As invited speakers,
Dr. Cheng has visited many institutes at foreign countries
and attended at international conferences. |
|
| |
|
